Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | PPID | Q08752 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | RARG | P13631 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29436986 | 1.00 | MME (0.46) | MMEANPEPPPIDCYP3A4CYP2C19 | |
| SCHEMBL29977652 | 1.00 | MME (0.46) | MMEANPEPPPIDCYP3A4CYP2C19 | |
| SCHEMBL389351 | 1.00 | MME (0.46) | MMEANPEPPPIDCYP3A4CYP2C19 | |
| SCHEMBL29436985 | 1.00 | MME (0.46) | MMEANPEPPPIDCYP3A4CYP2C19 | |
| SCHEMBL489493 | 1.00 | MME (0.46) | MMEANPEPPPIDCYP3A4CYP2C19 | |
| SCHEMBL7431612 | 0.93 | CYP3A4 (0.48) | MMEANPEPCYP3A4CYP2C19GAA | |
| SCHEMBL7431614 | 0.93 | CYP3A4 (0.48) | MMEANPEPCYP3A4CYP2C19GAA | |
| SCHEMBL28000637 | 0.90 | MME (0.47) | MMEANPEPPPIDCYP3A4CYP2C19 | |
| SCHEMBL21239953 | 0.89 | LTA4H (0.53) | MMEANPEPLTA4H | |
| SCHEMBL21239952 | 0.89 | LTA4H (0.53) | MMEANPEPLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200038379-A1 | PHARMACEUTICAL COMPOSITION | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2020-02-06 | — | — | US | claimed |
| CN-110237072-A | The preparation method of pharmaceutical composition | 武汉朗来科技发展有限公司 | 2019-09-17 | — | — | CN | claimed |
| WO-2019170135-A1 | MEDICINE COMPOSITION PREPARATION METHOD | 武汉朗来科技发展有限公司 | 2019-09-12 | — | — | WO | claimed |
| US-20190275046-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-09-12 | — | — | US | claimed |
| WO-2019170136-A1 | PHARMACEUTICAL FORMULATION AND USE THEREOF | 武汉朗来科技发展有限公司 | 2019-09-12 | — | — | WO | claimed |
| EP-3524250-A1 | PHARMACEUTICAL COMPOSITION | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2019-08-14 | — | — | EP | claimed |
| WO-2018211479-A1 | STABILIZED COMPOSITIONS OF ANGIOTENSIN II INHIBITORS AND NEUTRAL ENDOPEPTIDASE INHIBITORS AND PROCESS FOR PREPARATION THEREOF | LUPIN LIMITED (IN) | 2018-11-22 | — | — | WO | claimed |
| US-20160038494-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. | 2016-02-11 | — | — | US | claimed |
| US-20120138506-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | claimed |
| JP-4820056-B2 | — | — | 2011-11-24 | — | — | JP | claimed |
| EP-1467728-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VALSARTAN AND NEP INHIBITORS | Novartis AG (CH) | 2004-10-20 | — | — | EP | claimed |
| US-20030144215-A1 | Angiotensin antagonist valsartan and an enkephalinase inhibitor; used to treat cardiovascular disorders | NOVARTIS PHARMACEUTICALS CORPORATION | 2003-07-31 | — | — | US | claimed |
| WO-2003059345-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VALSARTAN AND NEP INHIBITORS | NOVARTIS AG (CH) | 2003-07-24 | — | — | WO | claimed |
| EP-0605589-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES OR NEUTRAL ENDOPEPTIDASE INHIBITORS FOR TREATING OR PREVENTING MYOINTIMAL PROLIFERATION | SCHERING CORPORATION (US) | 1994-07-13 | — | — | EP | claimed |
| WO-1993010773-A1 | USE OF NEUTRAL ENDOPEPTIDASE INHIBITORS IN THE TREATMENT OF LEFT VENTRICULAR HYPERTROPHY | SCHERING-PLOUGH S.P.A. (IT) | 1993-06-10 | — | — | WO | claimed |
| WO-1993005809-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES OR NEUTRAL ENDOPEPTIDASE INHIBITORS FOR TREATING OR PREVENTING MYOINTIMAL PROLIFERATION | SCHERING CORPORATION (US) | 1993-04-01 | — | — | WO | claimed |
| EP-0533084-A1 | Pharmaceutical compositions comprising natriuretic peptides or neutral endopeptidase inhibitors for treating and preventing myointimal proliferation | SCHERING CORPORATION (US) | 1993-03-24 | — | — | EP | claimed |
| WO-1992018159-A1 | USE OF NEUTRAL ENDOPEPTIDASE INHIBITORS IN THE TREATMENT OF NEPHROTOXICITY | SCHERING CORPORATION (US) | 1992-10-29 | — | — | WO | claimed |
| EP-0509442-A1 | Use of neutral endopeptidase inhibitors in the treatment of nephrotoxicity | SCHERING CORPORATION (US) | 1992-10-21 | — | — | EP | claimed |
| US-4929641-A | DIURETICS, ANGIOTENSIN CONVERTING ENZYMES | SCHERING CORPORATION (US) | 1990-05-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144215-A1 | Angiotensin antagonist valsartan and an enkephalinase inhibitor; used to treat cardiovascular disorders | MME, REN, AGTR1 | MME 1/4885ANPEP 27/4885PPID 2266/4885 |
| US-20120138506-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | REN, MME, ACE | MME 2/4885ANPEP 29/4885PPID 2424/4885 |
| US-20160038494-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | MME 12/4885ANPEP 55/4885PPID 1934/4885 |
| US-20200038379-A1 | PHARMACEUTICAL COMPOSITION | MME, ANPEP, TMPRSS15 | MME 1/4885ANPEP 2/4885PPID 1391/4885 |
| US-20190275046-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | MME 12/4885ANPEP 55/4885PPID 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.